Arix Bioscience Dirección

Dirección controles de criterios 0/4

We currently do not have sufficient information about the CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	1.5yrs

Actualizaciones recientes de la dirección

Recent updates

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Jan 13

CEO

Arix Bioscience no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tom Davidson	COO & CFO	less than a year	sin datos	sin datos
Laura Craig	Investor Relations Officer	less than a year	sin datos	sin datos
Tassos Konstantinou	Managing Director	less than a year	sin datos	sin datos
Jade Fletcher	Financial Controller	1.1yrs	sin datos	sin datos
Felix Breyer	Associate	no data	sin datos	sin datos
Roy Bartel-Taverner	Analyst	no data	sin datos	sin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: ARIX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peregrine David Euan Moncreiffe	Independent Non-Executive Chairman	2.8yrs	UK£150.00k	0.58% £ 1.0m
Andrew Smith	Independent Non-Executive Director	1.5yrs	UK£33.00k	sin datos
Debra Barker	Senior Independent Director	1.5yrs	UK£38.00k	0.040% £ 71.0k

1.5yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: ARIX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Arix Bioscience Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Arix Bioscience plc Announces Resignation of Directors

Independent Non-Executive Chairman recently bought UK£69k worth of stock

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Price target increased to UK£2.56

Less than half of directors are independent

Independent Non-Executive Chairman recently bought UK£78k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Price target increased to UK£2.56

Less than half of directors are independent

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Price target increased to UK£2.56

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

New 90-day high: UK£2.22

Executive Chairman recently bought UK£377k worth of stock

Investor sentiment improved over the past week

New 90-day high: UK£1.96

Market bids up stock over the past week

Analysts update estimates

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: UK£1.60

Price target raised to UK£1.71

New 90-day high: UK£1.12

New 90-day high - UK£0.97

Price target raised to UK£1.40

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

CEO

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad